[Current Status and Future Direction of Cancer Genomic Medicine].
Cancer gene panel testing has been approved in Japan. Precision medicine will be implemented in Japanese clinical practice. Clinical sequencing is expected to use for treatment decision for each patient. As a predictive biomarker of immune-checkpoint inhibitor(ICI), tumor mutation burden as well as PD-L1 IHC is under evaluating in several clinical settings. MSI-test was approved as companion diagnostics for an ICI. These markers are estimated by the cancer gene panel testing. These genomic testing proceed precision medicine for cancer patients.